Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19

Novikov P.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Brovko M.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Akulkina L.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Nadtocheeva V.: Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia

Potapov P.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia. Department of Internal Medicine, Lomonosov Moscow State University, Moscow, Russia

Moiseev S.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Download in PDF

Summary

Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration.

Key words

COVID-19, hyperinflammatory syndrome, cytokine storm, IL-6 inhibitors, olokizumab.